This is a randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
To evaluate, in a randomised phase 2 study, the efficacy of paclitaxel with or without the MEK inhibitor GSK1120212 (of which the most tolerable dose has been confirmed) or pazopanib in wild type BRAF metastatic melanoma, stratifying for NRAS mutation status.
- Progression free survival
- Objective response rate.
- Progression free survival at 6 months
- Safety of the GSK1120212/paclitaxel and pazopanib/paclitaxel combination
- Overall survival.